SPRB Stock Touches 52-Week Low at $0.34 Amid Steep Decline

Published 12/03/2025, 17:12
SPRB Stock Touches 52-Week Low at $0.34 Amid Steep Decline

Spruce Biosciences Inc (SPRB) stock has hit a 52-week low, trading at $0.34, with a market capitalization of just $14.74 million, as the company faces a challenging period marked by a significant downturn in its market valuation. According to InvestingPro analysis, the stock appears undervalued at current levels, with analyst price targets ranging from $1 to $3. Over the past year, SPRB has seen its stock price plummet, reflecting a staggering 1-year change of -93.13%. This sharp decline has alarmed investors and analysts alike, as the biopharmaceutical company grapples with the pressures of a competitive industry and investor sentiment. Despite the challenges, the company maintains a strong liquidity position with a current ratio of 5.36, though InvestingPro data indicates it’s quickly burning through cash. The current price level represents a critical juncture for Spruce Biosciences, as stakeholders closely monitor the company’s strategic moves to recover from this low point. Discover 11 more key insights about SPRB with an InvestingPro subscription.

In other recent news, Spruce Biosciences, Inc. has announced a change in its executive leadership. The company’s Chief Medical (TASE:BLWV) Officer, Dr. Ralph William Charlton III, will be departing at the end of December 2024. In connection with his departure, Dr. Charlton will receive severance benefits, including a lump sum payment of $343,200 and nine months of COBRA coverage, contingent upon a release of claims. Following this change, Spruce Biosciences has appointed Dr. Kirk Ways as the interim Chief Medical Officer. Dr. Ways, who has been on the company’s Board of Directors since June 2021, brings extensive experience from his previous roles, including serving as interim Chief Medical Officer at MBX Biosciences and Chief Medical Officer at Nuvelution Pharma, Inc. Dr. Ways also has a strong academic background, having held positions such as Director of the Diabetes Center and Vice Chairman for the Department of Internal Medicine at East Carolina School of Medicine. His contributions to academia include over one hundred publications in diabetes and cancer research. This leadership transition is part of Spruce Biosciences’ recent developments.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.